AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15705991
Drug: Inhaled colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled colistin
Trial: 15463836
Drug: Tobramycin nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin nebuliser solution (TNS) and Inhaled colistin
Trial: 10071997
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 0.1 microg x kg(‐1) x min(‐1) and saline bolus (5 mL)
Trial: 10071997
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion and remifentanil bolus (25 microg in 5 mL)
Trial: 10071997
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 0.05 microg x kg(‐1) x min(‐1) and remifentanil bolus (12.5 microg in 5 mL)
Trial: 10071997
Drug: Variable-rate continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable-rate continuous infusion of remifentanil
Trial: 6108607
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride 100 mg (89.4 mg of ranitidine base) twice daily
Trial: 4042390
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets twice daily
Trial: 6108607
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride (open treatment)
Trial: 25913479
Drug: Treatment response
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment response (bone marrow morphology on day 15 and 28)
Trial: 15031350
Drug: pH‐neutral low‐GDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH‐neutral low‐GDP solution (Balance)
Trial: 23369412
Drug: Ad4-H5-Vtn (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad4-H5-Vtn (all doses combined)
Trial: 21452293
Drug: Atacicept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (25 mg, 75 mg, or 150 mg)
Trial: 16606972
Drug: Pathologic nodal
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Iodal HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathologic nodal status after chemotherapy
Trial: 12488303
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m², 3-weekly cycles, up to 3 cycles)
Trial: 15116057
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m²)
Trial: 8618283
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no chemotherapy)
Trial: 1438493
Drug: Pentobarbital (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (150 mg)
Trial: 30430635
Drug: Non-face-to-face group
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-face-to-face group (NFG) using a tablet for the same Go lessons
Trial: 26811534
Drug: CELF4 rs1786814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CELF4 rs1786814 GG genotype with anthracycline exposure > 300 mg/m2
Trial: 25268802
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg or higher
Trial: 22791245
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of 50 mg atenolol
Trial: 22791245
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of 50 mg atenolol
Trial: 12204875
Drug: Control device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control device (inactive oral appliance)
Trial: 10037433
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride per day for 6 months
Trial: 1812476
Drug: Euphylong (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphylong (once daily at 2000 hours)
Trial: 31893705
Drug: Matrix-based formulation
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-based formulation of the iterative randomized stimulation and averaging (IRSA) method
Trial: 373989
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg for 2 weeks)
Trial: 31984696
Drug: Symbiotic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic combination (Lactobacillus and Bifidobacterium with fructo‐ and galacto‐oligosaccharides)
Trial: 29581669
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) for 4 sessions with 3 day-intervals
Trial: 26341262
Drug: 4-day use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day use of infusion sets
Trial: 26341262
Drug: 2-day use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day use of infusion sets
Trial: 20921909
Drug: Glutamic acid
RxNorm normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamic acid 1.5 grams daily orally in 3 divided doses during the 4-week induction with vincristine (1.5 mg/m² IV weekly)
Trial: 19396409
Drug: Trimetazidine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (twice daily)
Trial: 11243947
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily)
Trial: 9645184
Drug: Levothyroxine in
RxNorm normalized name: levothyroxine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine in a weight‐adapted dosage (75, 100 or 150 micrograms) plus 150 micrograms iodide
Trial: 3064775
Drug: Radiotherapy +
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy + tamoxifen (TAM), 30 mg daily for 1 year
Trial: 31451364
Drug: Tablet-based PAINUCope
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based PAINUCope intervention focused on barriers to pain management, pain, and analgesic adherence
Trial: 23991896
Drug: subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous immunotherapy with mixed depigmented‐polymerized birch and grass pollen extract
Trial: 15493172
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy for twelve cytology-negative patients (control group)
Trial: 11550726
Drug: Increased therapist
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased therapist self-disclosure during treatment
Trial: 11550726
Drug: No therapist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapist self-disclosure during treatment
Trial: 24260825
Drug: Nitazoxanide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (100 mg and 200 mg every 12 hours for 3 days)
Trial: 20374563
Drug: Continuous antiretroviral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antiretroviral therapy (C-ART)
Trial: 8408738
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 mg)
Trial: 3933067
Drug: Mepindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol (5 mg)
Trial: 3933067
Drug: Salbutamol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (20 mg)
Trial: 30055046
Drug: Samidorphan 1
RxNorm normalized name: samidorphan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samidorphan 1 mg/d
Trial: 30055046
Drug: Samidorphan 10
RxNorm normalized name: samidorphan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samidorphan 10 mg/d
Trial: 27030279
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab treatment
Trial: 15897845
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral rofecoxib
Trial: 11016665
Drug: Barrier creams
RxNorm normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier creams (3 representative commercial barrier creams)
Trial: 11016665
Drug: Control skin
RxNorm normalized name: ALLANTOIN 5 mg in 1 mL TOPICAL GEL [SkinCeuticals Advanced Scar Control Skin Protectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control skin (no barrier cream used)
Trial: 1620139
Drug: Physostigmine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.02 mg/kg)
Trial: 6137231
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg/kg)
Trial: 6151914
Drug: Oxatomide 30
RxNorm normalized name: oxatomide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide 30 mg b.i.d. for 2 months
Trial: 30661474
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d sodium diet
Trial: 29278529
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL sodium chloride 0.9 (placebo)
Trial: 27270263
Drug: L‐thyroxine replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐thyroxine replacement therapy
Trial: 24610399
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) and quitline referral (Group MNQ)
Trial: 24610399
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) and quitline referral (Group UNQ)
Trial: 19811890
Drug: Coordination therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordination therapy (CTh)
Trial: 15882280
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin anticoagulation
Trial: 7995617
Drug: Continuous plus
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous plus pulsatile overnight GH administration (50% constant delivery + 3 pulses)
Trial: 7995617
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injection of GH
Trial: 3593904
Drug: Flurbiprofen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (oral doses)
Trial: 26653112
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU daily vitamin D3
Trial: 26562709
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein (12 g protein, 7 g essential amino acids)
Trial: 26562709
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (12 g protein, 7 g essential amino acids)
Trial: 26562709
Drug: Rice milk
RxNorm normalized name: NIACINAMIDE 80 mg in 1 g / CAFFEINE 30 mg in 1 g / HYALURONIC ACID 60 mg in 1 g / PANAX GINSENG ROOT OIL 80 mg in 1 g TOPICAL CREAM [MOISTURIZING Soothing Eye Cream with aloe and rice milk]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice milk (nonprotein control, 12 g protein, 7 g essential amino acids)
Trial: 19560838
Drug: 1+1 hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1+1 hydromorphone patient‐driven protocol (1 mg IV hydromorphone followed by a second 1‐mg dose 15 minutes later if requested)
Trial: 19560838
Drug: Traditional physician‐driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physician‐driven administration of opioids (any IV opioid at the discretion of the attending physician)
Trial: 19560838
Drug: 1+1 hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1+1 hydromorphone patient‐driven protocol and Traditional physician‐driven administration
Trial: 6373344
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (50 mg b.d. for the first three months, with possible increase of 50 mg after the third and/or sixth month if PaO2 increase is less than 5 mmHg and well tolerated)
Trial: 30286303
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk (200 mL daily, enriched with 3 μg of vitamin D3)
Trial: 30286303
Drug: Nonfortified milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfortified milk (200 mL daily, natural abundance of vitamin D3, about 1.5 μg)
Trial: 16755554
Drug: Pramipexole (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.125 to 0.75 mg/day)
Trial: 30768684
Drug: Oral briefing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral briefing followed by a 4-min planning discussion
Trial: 20621734
Drug: Erlotinib (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (EGFR tyrosine kinase inhibitor)
Trial: 16996172
Drug: Peru-15 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peru-15 vaccine (2x10^8 cfu)
Trial: 16996172
Drug: Peru-15 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peru-15 vaccine (2x10^7 cfu)
Trial: 16358380
Drug: Low-dosage levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage levothyroxine (L-T4) at an initial dosage of 3.21-5.81 microg/(kg.d), average of 16.25±3.87 microg/d, for a mean duration of therapy of 28.09±9.56 months.
Trial: 11528582
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg/week)
Trial: 9780524
Drug: Direct hypnotic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct hypnotic suggestions (Harvard Group Scale of Hypnotizability)
Trial: 9780524
Drug: Indirect hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indirect hypnotic suggestions (Alman Wexler Indirect Hypnotic Susceptibility Scale)
Trial: 3215160
Drug: Weight gain
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight gain prevention treatment (monthly newsletters, financial incentives, optional education course)
Trial: 26200520
Drug: Participant characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant characteristics (marital status, use of sleep medication, comorbidity, posttraumatic stress disorder, living arrangement)
Trial: 20938664
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg/month
Trial: 16798391
Drug: Dihydroartemisinin-piperaquine (6.3/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (6.3/50 mg/kg)
Trial: 16798391
Drug: Artesunate-mefloquine (12/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (12/25 mg/kg)
Trial: 12824948
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg per day)
Trial: 11070146
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.5 g)
Trial: 11070146
Drug: Sesame oil
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame oil (4.5 g)
Trial: 12955426
Drug: Heparin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin therapy alone
Trial: 25431225
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen Dripping Pills
Trial: 30741894
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (steroids and diuretics simultaneously for 2 weeks)
Trial: 30741894
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (diuretics for 2 weeks followed by steroids for another 2 weeks if no response)
Trial: 1150903
Drug: Indomethacin administered
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin administered concurrently with warfarin for five days
Trial: 1150903
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of warfarin administered before and after ten consecutive days of oral indomethacin administration
Trial: 17916877
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide intravenous bolus infusion over 2 min (BIG group)
Trial: 9619011
Drug: Intermittent perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent perfusion of cold crystalloid (St. Thomas Hospital solution) with hypothermic CPB
Trial: 16229019
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg b.i.d.
Trial: 7713856
Drug: Biperiden 2
RxNorm normalized name: biperiden 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2 mg b.i.d.
Trial: 2502974
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid rectal suppository (500 mg)
Trial: 2502974
Drug: Oral valproate
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral valproate sodium syrup (500 mg)
Trial: 9629401
Drug: Propranolol 60
RxNorm normalized name: propranolol 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 60 mg/day
Trial: 30431297
Drug: Practice of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice of therapy-acquired regulatory skills
Trial: 23746555
Drug: Liraglutide 1.8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8mg added to metformin followed by insulin detemir for 52 weeks (RT group)
Trial: 19927363
Drug: Immunosuppressive drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drug therapy (IDT) only
Trial: 8077353
Drug: Evening calcium
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening calcium supplementation (1000 mg for 14 days)
Trial: 8077353
Drug: Morning calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning calcium supplementation (1000 mg for 14 days)
Trial: 2807562
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg administered one hour before ESWL
Trial: 7224261
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (control group)
Trial: 31609396
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to another SSRI or to venlafaxine with cognitive behavioral therapy
Trial: 31609396
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to another SSRI or to venlafaxine without cognitive behavioral therapy
Trial: 23290112
Drug: 3-month neoadjuvant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month neoadjuvant hormonal therapy (NHT) before (125)I permanent seed implantation
Trial: 17579840
Drug: ropinirole 0.5
RxNorm normalized name: ropinirole 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropinirole 0.5 mg
Trial: 17579840
Drug: ropinirole 0.25
RxNorm normalized name: ropinirole 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropinirole 0.25 mg
Trial: 15956965
Drug: ZD4054 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 (single oral dose)
Trial: 15956965
Drug: ZD4054 (ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 (ascending single-dose)
Trial: 7437242
Drug: Indacrinone (MK-196)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (MK-196) 60 mg
Trial: 7437242
Drug: Indacrinone (MK-196)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (MK-196) 40 mg
Trial: 22198243
Drug: CA-125 velocity
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA-125 velocity (average velocity of 19.749 U/ml per month)
Trial: 22198243
Drug: Non-cancer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cancer group (average velocity of 0.035 U/ml per month)
Trial: 17889549
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and Maxillofacial Surgery (OMFS) patients
Trial: 17889549
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups (surgical, dental, and general practitioners/internal medicine patients)
Trial: 6773613
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg/day
Trial: 10670264
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg subarachnoid morphine with bupivacaine (group M)
Trial: 6885575
Drug: Respiratory acidosis
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory acidosis (induced by 5% CO2 inhalation)
Trial: 24735128
Drug: 360 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 μg budesonide